source
- Adicet's off-the-shelf CAR-T shows 50% kidney response in early lupus trialAn early-stage study of Adicet Bio's off-the-shelf gamma-delta CAR-T cell therapy reported encouraging results in patients with lupus nephritis. After a year of follow-up, half of the evaluable pa…
- FDA proposes new BsUFA IV commitment letter to streamline biosimilar reviewsThe U.S. Food and Drug Administration released a draft commitment letter for the Biosimilar User Fee Act (BsUFA IV) program, highlighting several departures from the existing biosimilar review fram…